---
title: "Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286009811.md"
description: "Analyst Brendan Smith of TD Cowen has reiterated a Buy rating on Halozyme, maintaining a price target of $96. He cites strong growth driven by ENHANZE-based products and a new $1B share repurchase authorization as indicators of management's confidence. Smith believes the stock's growth potential is underappreciated, supported by robust first-quarter results and a long runway for future ENHANZE launches. H.C. Wainwright also supports this view with a Buy rating and a $95 price target."
datetime: "2026-05-11T23:45:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286009811.md)
  - [en](https://longbridge.com/en/news/286009811.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286009811.md)
---

# Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target

Analyst Brendan Smith of TD Cowen maintained a Buy rating on Halozyme, retaining the price target of $96.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Brendan Smith has given his Buy rating due to a combination of factors that highlight Halozyme’s strong and durable growth profile. He points to a robust first quarter, marked by materially higher royalty and total revenues than market expectations, driven by key ENHANZE-based products and strong operating leverage that lifted earnings meaningfully above Street estimates.

He also emphasizes the new $1B share repurchase authorization, with a significant portion slated for 2026, as a clear signal of management’s confidence in both near-term performance and the longevity of the royalty model, especially since current guidance does not yet reflect any buyback benefit. With a long runway of potential ENHANZE launches into the next decade, reinforced by proprietary scenario work, he maintains that the stock’s top- and bottom-line growth prospects remain underappreciated, supporting his unchanged $96 price target and Buy recommendation.

Smith covers the Healthcare sector, focusing on stocks such as Halozyme, Codexis, and Repligen. According to TipRanks, Smith has an average return of 5.3% and a 43.32% success rate on recommended stocks.

In another report released on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $95.00 price target.

### Related Stocks

- [HALO.US](https://longbridge.com/en/quote/HALO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [CDXS.US](https://longbridge.com/en/quote/CDXS.US.md)
- [RGEN.US](https://longbridge.com/en/quote/RGEN.US.md)

## Related News & Research

- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)